PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors.

新闻稿Memo Therapeutics AG任命Paul Carter为主席病毒学和商业专业知识将支持抗BKV的III期准备和商业准备广泛的公共和私人市场经验，继2024年7月8日在瑞士苏黎世Schlieren的多家生物制药公司担任高管职位后-Memo Therapeutics AG（或“MTx”），一家将独特的免疫反应转化为治疗病毒感染和癌症的优质药物的晚期生物技术公司，今天宣布任命Paul Carter为董事会主席。

Paul has had an extensive executive career in the biopharma space, with commercial and M&A expertise spanning North America, Europe, and Asia. He has over 10 years of experience working in the virology field at Gilead Sciences Inc., most recently as EVP and Chief Commercial Officer, where he oversaw over $30 billion dollars of sales and contributed to multiple M&A transactions.

保罗在生物制药领域拥有广泛的高管职业生涯，拥有横跨北美、欧洲和亚洲的商业和并购专业知识。他在吉利德科学公司（Gilead Sciences Inc.）病毒学领域拥有10多年的工作经验，最近担任执行副总裁兼首席商务官，负责管理300多亿美元的销售额，并为多项并购交易做出了贡献。

Prior to this, he spent seven years at GlaxoSmithKline (“GSK”), where he was responsible for all GSK interests in the Greater China region. Paul will replace Elias Papatheodorou, who was instrumental in the transition of MTx from a preclinical-stage to a well-funded clinical-stage company with an experienced and well-rounded management team.

在此之前，他在葛兰素史克（“葛兰素史克”）工作了七年，负责葛兰素史克在大中华地区的所有利益。保罗将取代埃利亚斯·帕帕西奥多罗（EliasPapatiodorou），后者在MTx从临床前阶段过渡到资金充足的临床阶段公司的过程中发挥了重要作用，拥有经验丰富且全面的管理团队。

Elias is transitioning into an executive role at a European biotech and will hand-over to Paul as part of a planned succession process. Erik van den Berg, CEO of MTx, commented: “We are delighted to welcome Paul Carter as our Chairperson. Paul’s track record and commercial and M&A expertise make him a perfect addition to our team.

埃利亚斯（Elias）正在欧洲一家生物技术公司（European biotech）担任高管，并将作为计划继任过程的一部分移交给保罗（Paul）。。

We look forward to his advice and support in driving the Company’s continued success as we advance into a Phase III ready organization. To El.

我们期待着他的建议和支持，在我们进入第三阶段准备就绪的组织时，推动公司继续取得成功。到El。